A new paper from the SHARP Clinical Research Collaboration, has been published online in Respiratory Research.
Entitled, ‘Use of long-acting muscarinic antagonists for severe asthma: insights from clinicians in the SHARP network’, the paper was led by Dr. Alessandro Marcon and Marco Caminati.
The paper shares findings from the SHARP European survey of 470 respiratory clinicians. It found that the use of inhaled long-acting muscarinic antagonists (LAMAs) for severe asthma varies widely across countries. While most clinicians expect LAMA treatment to improve quality of life, lung function, and reduce exacerbations, many face barriers such as lack of reimbursement and differing local practices.
Clinicians in Eastern and Southern Europe reported greater confidence in LAMA use than those in Northern and Western Europe. Overall, clearer international guidance is needed to define LAMA’s role in severe asthma management.
Read a lay summary of the paper
